Myriad Genetics Blog Blog > Prolaris® is Helping Urologists Reimagine Prostate Cancer Care Prolaris® is Helping Urologists Reimagine Prostate Cancer Care November 2, 2021 Provider Blog Urology This year’s LUGPA theme centers on re-imagining the practice of Urology. What better time than now to discover how incorporating genetic testing into your practice can provide you with customized and clinically actionable information to personalize prostate cancer care. Order a Physician Guide Prolaris now has 2 validated thresholds to make treatment decisions easier Prolaris is a prognostic, tumor-based biomarker test that measures the aggressiveness of your patient’s prostate tumor. Combining tumor aggressiveness with traditional, diagnostic features like PSA, Gleason, and tumor stage, Prolaris is helping urologists everywhere personalize cancer care. Our easy-to-read, customized results will help you determine who can safely pursue active surveillance, who needs treatment, who can benefit from ADT + RT and who can safely avoid these treatments. Watch the video below to see how the Prolaris test results can customize your prostate cancer care. Learn how Prolaris can benefit your practice Order a Physician Guide Why EVERY MAN needs Prolaris Every cancer is different. One major aspect of cancer is that the affected cells are growing at an accelerated rate, but how quickly the cancer grows, depends on the individual. The genes that provide information on the rate of cancer cell growth are called Cell Cycle Proliferation Genes (CCP). The Prolaris test looks at these unique CCP genes to help clarify your patient’s cancer aggressiveness, providing you unparalleled genetic insights and giving you confidence to customize each patient’s treatment. Learn more about Prolaris Join us at our LUGPA Symposium References Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer: Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7. 3. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612-618.